<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3ac061d0-8849-41e9-a962-569469f6e15c"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use ALPHAGAN</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold">
         <sup> </sup>
      </content>
      <content styleCode="bold"> P safely and effectively.  See full prescribing information for ALPHAGAN</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold">
         <sup> </sup>
      </content>
      <content styleCode="bold"> P.  </content>
      <br/>
      <content styleCode="bold">   </content>
      <br/>
      <content styleCode="bold">ALPHAGAN</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval:</content>
      <content styleCode="bold"> 1996 </content>
      <br/>
   </title>
   <effectiveTime value="20240627"/>
   <setId root="264c4494-c225-486f-888a-caaf36be46b3"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="144796497" root="1.3.6.1.4.1.519.1"/>
            <name>Allergan, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b7933c98-9e1a-4af0-a4c5-37f7f57a34f0"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250422"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0023-9321" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ALPHAGAN P</name>
                        <formCode code="C60992" displayName="SOLUTION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>brimonidine tartrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G538EBV4VF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9321-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060125"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9321-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060125"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9321-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060125"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9321-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20060125"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021770" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060125"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0023-9177" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ALPHAGAN P</name>
                        <formCode code="C60992" displayName="SOLUTION/ DROPS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>brimonidine tartrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4S9CL2DY2H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BRIMONIDINE TARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="E6GNX3HHTE" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BRIMONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M4I0D6VV5M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G538EBV4VF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9177-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20010710"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9177-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20010710"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" displayName="BOTTLE, DROPPER" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0023-9177-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20010710"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021262" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20010710"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" displayName="OPHTHALMIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="7d88eb4e-e9e8-457e-8353-bd4f1b5410d3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
		     
	<content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>
                     <content styleCode="bold"> P</content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>(brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. </paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>® </sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_2_DOSAGE_AND">
               <id root="db0b9e41-4d97-4cc0-b398-95a1a42b05e2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>The recommended dose is one drop of <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>
                     <content styleCode="bold"> P</content> in the affected eye(s) three times daily, approximately 8 hours apart. <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <sup> </sup>
                     </content>
                     <content styleCode="bold"> P</content> ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. </paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop in the affected eye(s), three times daily, approximately 8 hours apart. (<linkHtml href="#_2_DOSAGE_AND">2</linkHtml>)  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="e5aed4a9-f36b-428e-ba33-c6d7357c5909"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Solution containing 1 mg/mL or 1.5 mg/mL brimonidine tartrate. </paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Solution containing 1 or 1.5 mg/mL brimonidine tartrate. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="42c35ead-1a06-4102-83ca-a7a13d77e794"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Neonates and infants (under the age of 2 years). (<linkHtml href="#_4_1_Neonates_and">4.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_4_1_Neonates_and">
                     <id root="70226ee6-567f-4ae5-84c4-67ba2b1c7b62"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.1</content>
                        <content styleCode="bold">
		     
	Neonates and Infants (</content>
                        <content styleCode="bold">under the age of 2 years</content>
                        <content styleCode="bold">)</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> </content>is contraindicated in neonates and infants (under the age of 2 years).</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8ac16ab9-2041-4e15-93a3-4868afef8492"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">4.2</content>
                        <content styleCode="bold">
		     
	Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph> <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold"> </content>is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8fbcdf78-c5d7-48aa-a2fc-237b7b8ac305"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
		     
	<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potentiation of vascular insufficiency. (<linkHtml href="#_5_1_Potentiation_of">5.1</linkHtml>)
		     
	</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Potentiation_of">
                     <id root="22c74d09-6a8f-4812-a8e0-1d9323da4cec"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
                        <content styleCode="bold">
		     
	Potentiation of Vascular Insufficiency</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content> may potentiate syndromes associated with vascular insufficiency. <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content> should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c7e7fe59-8889-486b-91c2-cd482fcc7399"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2</content>
		     
	<content styleCode="bold">Severe </content>
                        <content styleCode="bold">C</content>
                        <content styleCode="bold">ardiovascular Disease</content>
                     </title>
                     <text>
                        <paragraph>Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Contamination_of">
                     <id root="46737495-b094-4a06-a080-582370e4dead"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3</content>
                        <content styleCode="bold">
		     
	Contamination of Topical Ophthalmic Products After Use</content>
                     </title>
                     <text>
                        <paragraph>There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_17_PATIENT_COUNSELING">Patient Counseling Information (17</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="909c74df-5a60-4751-b5d0-e30bb86535b3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
		     
	<content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1%-0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. (<linkHtml href="#_6_1_Clinical_Studies">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-678-1605 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Studies">
                     <id root="cac001fd-2ddc-4feb-9791-5906d70ffbcc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
                        <content styleCode="bold">
		     
	Clinical </content>
                        <content styleCode="bold">Studies</content>
                        <content styleCode="bold"> Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse reactions occurring in approximately 10-20% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5-9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. </paragraph>
                        <paragraph>Adverse reactions occurring in approximately 1-4% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: abnormal taste, allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.</paragraph>
                        <paragraph>The following reactions were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b9a9fa20-c03b-4ca1-ba2c-a2249ef56753"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
                        <content styleCode="bold">
		     
	Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following reactions have been identified during postmarketing use of brimonidine tartrate ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus, rash, and vasodilation), syncope, and tachycardia. Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b9164c1b-b427-42b9-9caf-7fc99453bc52"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7   </content>
		     
	<content styleCode="bold">DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Antihypertensives/cardiac glycosides may lower blood pressure. (<linkHtml href="#_7_1_Antihypertensives_Cardiac_Glyco">7.1</linkHtml>)<br/>
                           </item>
                           <item>Use with CNS depressants may result in an additive or potentiating effect. (<linkHtml href="#_7_2_CNS_Depressants">7.2</linkHtml>)<br/>
                           </item>
                           <item>Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine.  (<linkHtml href="#_7_3_Tricyclic_Antidepressants">7.3</linkHtml>)<br/>
                           </item>
                           <item>Monoamine oxidase inhibitors may result in increased hypotension. (<linkHtml href="#_7_4_Monoamine_Oxidase">7.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_Antihypertensives_Cardiac_Glyco">
                     <id root="d49ed81b-560f-4e2f-b952-d3640006bf65"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
                        <content styleCode="bold">
		     
	Antihypertensives/Cardiac Glycosides</content>
                     </title>
                     <text>
                        <paragraph>Because <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content> may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content>
                           <content styleCode="bold"> </content>is advised. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_2_CNS_Depressants">
                     <id root="b5fdb684-5c41-4b8b-afb1-b824cc4f8bc2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
                        <content styleCode="bold">
		     
	CNS Depressants</content>
                     </title>
                     <text>
                        <paragraph>Although specific drug interaction studies have not been conducted with <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold">
                              <sup> </sup>
                           </content>
                           <content styleCode="bold"> P</content>, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_3_Tricyclic_Antidepressants">
                     <id root="97ec46e9-a154-4676-99d0-722d1051e7cc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3</content>
                        <content styleCode="bold">
		     
	Tricyclic Antidepressants</content>
                     </title>
                     <text>
                        <paragraph>Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> in humans can lead to resulting interference with the IOP lowering effect. Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_4_Monoamine_Oxidase">
                     <id root="43c78260-54b9-45e9-bb9f-11d6baf1d97c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.4</content>
                        <content styleCode="bold">
		     
	Monoamine Oxidase Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="362adddf-fe78-4bb8-a8a2-5a9b142b9e32"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
		     
	<content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20240627"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Use with caution in children ≥ 2 years of age. (<linkHtml href="#_8_4_Pediatric_Use">8.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="85ca5c06-9c56-4f48-af94-88c22b5b3c11"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
                        <content styleCode="bold">
		     
	Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>Pregnancy Category B: Teratogenicity studies have been performed in animals. </paragraph>
                        <paragraph>Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. The highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5.0 mg/kg/day) achieved AUC exposure values 360- and 20-fold higher, or 260- and 15-fold higher, respectively, than similar values estimated in humans treated with <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> 0.1% or 0.15%, 1 drop in both eyes three times daily. </paragraph>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Because animal reproduction studies are not always predictive of human response, <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bd72662f-25ea-420c-8d73-08e3b542beb3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">3</content>
		     
	<content styleCode="bold">Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>It is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk. Because of the potential for serious adverse reactions from <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> in nursing infants,  a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_4_Pediatric_Use">
                     <id root="befd2932-7e00-4538-8789-0df84aa4cf32"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
                        <content styleCode="bold">
		     
	Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> is contraindicated in children under the age of 2 years <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_4_1_Neonates_and">Contraindications (4.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. During postmarketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine. The safety and effectiveness of brimonidine tartrate have not been studied in children below the age of 2 years.</paragraph>
                        <paragraph>In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse reactions with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50-83% in patients ages 2 to 6 years) and decreased alertness. In pediatric patients 7 years  of age (&gt;20 kg), somnolence appears to occur less frequently (25%). Approximately 16% of patients on brimonidine tartrate ophthalmic solution discontinued from the study due to somnolence.<content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5ef3143b-4129-45e0-96a7-d122a64f6d18"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
		     
	<content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="896839fa-60f4-4f3c-962c-e07d01e39e92"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6</content>
                        <content styleCode="bold">
		     
	Special Populations</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> has not been studied in patients with hepatic impairment. </paragraph>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> has not been studied in patients with renal impairment. The effect of dialysis on brimonidine pharmacokinetics in patients with renal failure is not known.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c1e74e4e-afa7-4301-b3b3-11c14f1a68c5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10</content>
		     
	<content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Very limited information exists on accidental ingestion of brimonidine in adults; the only adverse reaction reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> P</content> as part of medical treatment of congenital glaucoma or by accidental oral ingestion <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_4_Pediatric_Use">Use in Specific Populations (8.4)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. </paragraph>
               </text>
               <effectiveTime value="20240627"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8f5c4e58-8743-43e2-8396-430d89aa8ae9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) 0.1% or 0.15%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist (topical intraocular pressure lowering agent).  </paragraph>
                  <paragraph>The structural formula of brimonidine tartrate is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW= 442.24</paragraph>
                  <paragraph>In solution, <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) has a clear, greenish-yellow color. It has an osmolality of 250-350 mOsmol/kg and a pH of 7.4-8.0 (0.1%) or 6.9-7.4 (0.15%).</paragraph>
                  <paragraph>Brimonidine tartrate appears as an off-white to pale-yellow powder and is soluble in both water (0.6 mg/mL) and in the product vehicle (1.4 mg/mL) at pH 7.7. </paragraph>
                  <paragraph>Each mL of <content styleCode="bold">ALPHAGAN</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold"> P</content> contains the active ingredient brimonidine tartrate 0.1% (1 mg/mL) or 0.15% (1.5 mg/mL) with the inactive ingredients sodium carboxymethylcellulose; sodium borate; boric acid; sodium chloride; potassium chloride; calcium chloride; magnesium chloride; PURITE<sup>®</sup> 0.005% (0.05 mg/mL) as a preservative; purified water; and hydrochloric acid and/or sodium hydroxide to adjust pH.</paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The structural formula of brimonidine tartrate is brimonidine tartrate ophthalmic solution) 0.1% or 0.15%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist (topical intraocular pressure lowering agent).  
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alphagan-p-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="feb618b8-9ce2-42e2-8432-2843c7ef131a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20240627"/>
               <component>
                  <section>
                     <id root="df87d1b9-8b63-4fbc-b180-ae6ba000e99d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">
		     
	Mechanism of Action </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P</content> is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing.</paragraph>
                        <paragraph>Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4cffe137-fb6b-4dd7-9ce3-3ced4dd46b69"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
                        <content styleCode="bold">
		     
	Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The protein binding of brimonidine has not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>In humans, brimonidine is extensively metabolized by the liver. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Urinary excretion is the major route of elimination of brimonidine and its metabolites. Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine.  </paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="061921ca-327b-4113-8a25-a99f3002dd3c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
		     
	<content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20240627"/>
               <component>
                  <section>
                     <id root="ead7c9eb-8ede-443b-98a9-b0d31d259a87"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1 mg/kg/day in rats achieved 150 and 120 times or 90 and 80 times, respectively, the plasma C<sub>max</sub> drug concentration in humans treated with one drop of <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P </content>0.1% or 0.15% into both eyes 3 times per day, the recommended daily human dose.</paragraph>
                        <paragraph>Brimonidine tartrate was not mutagenic or clastogenic in a series of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three <content styleCode="italics">in vivo</content> studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay. </paragraph>
                        <paragraph>Reproduction and fertility studies in rats with brimonidine tartrate demonstrated no adverse effect on male or female fertility at doses which achieve up to approximately 125 and 90 times the systemic exposure following the maximum recommended human ophthalmic dose  of <content styleCode="bold">ALPHAGAN</content>
                           <content styleCode="bold">
                              <sup>®</sup>
                           </content>
                           <content styleCode="bold"> P </content>0.1% or 0.15%,<content styleCode="bold"> </content>respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240627"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="347c1692-4cad-47bd-9487-ad50ff8c58ab"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
		     
	<content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.</paragraph>
                  <paragraph>Clinical studies were conducted to evaluate the safety, efficacy, and acceptability of <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) 0.15% compared with <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup> administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) 0.15% is comparable in IOP lowering effect to <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup> (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.</paragraph>
                  <paragraph>A clinical study was conducted to evaluate the safety, efficacy, and acceptability of <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) 0.1% compared with <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup> administered three-times-daily in patients with open-angle glaucoma or ocular hypertension. Those results indicated that <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content> (brimonidine tartrate ophthalmic solution) 0.1% is equivalent in IOP lowering effect to <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup> (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg.</paragraph>
               </text>
               <effectiveTime value="20240627"/>
            </section>
         </component>
         <component>
            <section>
               <id root="dad18433-c1f3-4498-b01c-e5951d49a056"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
		     
	<content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content> is supplied sterile, in teal opaque plastic LDPE bottles and tips, with purple high impact polystyrene (HIPS) caps as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.1%</content>
                  </paragraph>
                  <paragraph>5 mL in 10 mL bottle
		     
	  NDC 0023-9321-05</paragraph>
                  <paragraph>10 mL in 10 mL bottle
		     
	NDC 0023-9321-10</paragraph>
                  <paragraph>15 mL in 15 mL bottle
		     
	NDC 0023-9321-15</paragraph>
                  <paragraph>
                     <content styleCode="bold">0.15%</content>
                  </paragraph>
                  <paragraph>5 mL in 10 mL bottle
		     
	  NDC 0023-9177-05</paragraph>
                  <paragraph>10 mL in 10 mL bottle
		     
	NDC 0023-9177-10</paragraph>
                  <paragraph>15 mL in 15 mL bottle
		     
	NDC 0023-9177-15 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage: </content>Store at 15<sup>o</sup>-25<sup>o</sup>C (59<sup>o</sup>-77<sup>o</sup>F). </paragraph>
               </text>
               <effectiveTime value="20240627"/>
            </section>
         </component>
         <component>
            <section ID="_17_PATIENT_COUNSELING">
               <id root="15fd6d54-7505-4aea-bc5f-e41c1b9cfb9b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
		     
	<content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Patients should be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions <content styleCode="italics">[see </content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_3_Contamination_of">Warnings and Precautions (5.3)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.</paragraph>
                  <paragraph>Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container. </paragraph>
                  <paragraph>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</paragraph>
                  <paragraph>As with other similar medications, <content styleCode="bold">ALPHAGAN</content>
                     <sup>®</sup>
                     <content styleCode="bold"> P</content>
                     <content styleCode="bold"> </content>may cause fatigue and/or drowsiness in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness. </paragraph>
                  <paragraph>Distributed by:<br/>AbbVie Inc.<br/>North Chicago, IL 60064</paragraph>
                  <paragraph>© 2024 AbbVie.  All rights reserved.<br/>ALPHAGAN P and its design and PURITE are trademarks of Allergan, Inc., an AbbVie company.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000002"/>
                  </paragraph>
                  <paragraph>20086819R2</paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Abbvie logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alphagan-p-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="94a6a60c-de4b-49d3-820d-220984ff1b22"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>abbvie<br/>NDC  0023-9321-10<br/>Alphagan<sup>®</sup> P<br/>(brimonidine tartrate <br/>ophthalmic solution) <br/>0.1%<br/>10 mL<br/>Rx only <br/>sterile</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000003"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <component>
                  <observationMedia ID="MM02000003">
                     <text>PRINCIPAL DISPLAY PANEL
abbvie
NDC  0023-9321-10
Alphagan® P
(brimonidine tartrate 
ophthalmic solution) 
0.1%
10 mL
Rx only 
sterile
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alphagan-p-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2d853059-3ec0-4bd0-a376-15bfbf406324"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>abbvie<br/>NDC  0023-9177-10<br/>Alphagan<sup>®</sup> P<br/>(brimonidine tartrate <br/>ophthalmic solution) <br/>0.15%<br/>10 mL<br/>Rx only <br/>sterile</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000004"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240627"/>
               <component>
                  <observationMedia ID="MM02000004">
                     <text>PRINCIPAL DISPLAY PANEL
abbvie
NDC  0023-9177-10
Alphagan® P
(brimonidine tartrate 
ophthalmic solution) 
0.15%
10 mL
Rx only 
sterile
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alphagan-p-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>